Paper17517853
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE and 1 other. N Engl J Med, 2007. Cited by 3,569 papers, by iCite.
Cite this record
ConductScience Library. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Papers, record 17517853. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17517853
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Hypoglycemic Agents | Major topic |
| Myocardial Infarction | Major topic |
| Thiazolidinediones | Major topic |
| Glycated Hemoglobin | |
| Humans | |
| Middle Aged | |
| Odds Ratio | |
| Randomized Controlled Trials as Topic | |
| Risk Assessment | |
| Rosiglitazone |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00868933 | Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease | Background |
Source ClinicalTrials.gov
Comments and corrections14
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 17517854 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17517854 | PubMed |
| Comment in | 17551160 | Rosiglitazone--continued uncertainty about safety. | https://conductscience.org/library/papers/17551160 | PubMed |
| Comment in | 17551161 | Rosiglitazone and cardiotoxicity--weighing the evidence. | https://conductscience.org/library/papers/17551161 | PubMed |
| Comment in | 17551162 | The record on rosiglitazone and the risk of myocardial infarction. | https://conductscience.org/library/papers/17551162 | PubMed |
| Comment in | 17761600 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17761600 | PubMed |
| Comment in | 17806134 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17806134 | PubMed |
| Comment in | 17806135 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17806135 | PubMed |
| Comment in | 17806136 | Rosiglitazone and cardiovascular risk. | https://conductscience.org/library/papers/17806136 | PubMed |
| Comment in | 17848926 | Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus? | https://conductscience.org/library/papers/17848926 | PubMed |
| Comment in | 17925798 | Is rosiglitazone associated with increased risk for cardiovascular events? | https://conductscience.org/library/papers/17925798 | PubMed |
| Comment in | 17975868 | Review: rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes. | https://conductscience.org/library/papers/17975868 | PubMed |
| Comment in | 18022724 | Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). | https://conductscience.org/library/papers/18022724 | PubMed |
| Comment in | 18063729 | Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes. | https://conductscience.org/library/papers/18063729 | PubMed |
| Comment in | 20647188 | Don't mess with the DSMB. | https://conductscience.org/library/papers/20647188 | PubMed |
Cited by1,539
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,569 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42839993 | Reduced serum adiponectin and exercise predict depression in chronic heart failure patients and affect depressive-like behaviors in a mouse model. | Front Physiol | 2026 | https://conductscience.org/library/papers/42839993 | PubMed |
| 42774918 | Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease. | Kidney Int Rep | 2026 | https://conductscience.org/library/papers/42774918 | PubMed |
| 42755691 | Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization. | Hypertension | 2026 | https://conductscience.org/library/papers/42755691 | PubMed |
| 42719321 | Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH). | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42719321 | PubMed |
| 42695164 | The Portability of Surrogate Endpoints. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42695164 | PubMed |
| 42667518 | Antidiabetic medications and arterial thrombotic risk reduction: a narrative review. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/42667518 | PubMed |
| 42614881 | The Substrate-Engine Model of Ferroptosis: Stage-Specific Targeting of Acyl-CoA Synthetase Long-Chain Family Member 4 and 5‑Lipoxygenase in Alzheimer's Disease. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42614881 | PubMed |
| 42584735 | Peroxisome proliferator-activated receptor gamma (PPARγ) as a mechano-metabolic transducer: coordinating lipid homeostasis through mechanical cues. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42584735 | PubMed |
| 42568490 | Incretin analogues as cardiovascular agents: a state-of-the-art review. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42568490 | PubMed |
| 42466348 | Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42466348 | PubMed |
| 42440427 | Effectiveness of low-dose SGLT2 inhibitors in diabetic patients with heart failure: a nationwide cohort study. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42440427 | PubMed |
| 42354854 | The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review. | Microorganisms | 2026 | https://conductscience.org/library/papers/42354854 | PubMed |
| 42351310 | From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling. | Cardiovasc Diabetol Endocrinol Rep | 2026 | https://conductscience.org/library/papers/42351310 | PubMed |
| 42316327 | Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42316327 | PubMed |
| 42292795 | Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42292795 | PubMed |
| 42283795 | Analytic Misjudgment of Drug Safety Evidence and Causality: From the Prosecutor's Fallacy and Simpson's Paradox to Artificial Intelligence. | Drug Saf | 2026 | https://conductscience.org/library/papers/42283795 | PubMed |
| 42157659 | Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea. | J Diabetes Investig | 2026 | https://conductscience.org/library/papers/42157659 | PubMed |
| 42060802 | After the green light: Evaluating drugs in Phase IV studies. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/42060802 | PubMed |
| 42016855 | Neuron-targeted 2-deoxyglucose-dendrimer-rosiglitazone nanotherapy mitigates neuroinflammation and cognitive deficits in pediatric traumatic brain injury. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42016855 | PubMed |
| 42006047 | Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden. | Toxicol Rep | 2026 | https://conductscience.org/library/papers/42006047 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17517853
GET https://conductscience.org/api/papers/v1/17517853/cited_by?page=2